DJS Law Group says Capricor investors may join securities suit over Deramiocel disclosures
The PR Newswire release says the case covers buyers of Capricor Therapeutics shares between Dec. 17, 2025 and July 26, 2026.
DJS Law Group said on Aug. 13 that investors may be able to join a securities class action against Capricor Therapeutics Inc. over statements about Deramiocel, a modified statistical analysis plan and a Biologics License Application resubmission.
The press release says the lawsuit cites Section 10(b), Section 20(a) and SEC Rule 10b-5 and covers shareholders who bought CAPR during the class period of Dec. 17, 2025, through July 26, 2026. The filing alleges that Capricor made false and misleading statements to the market.
According to the release, the complaint says Capricor changed the statistical analysis plan used to evaluate clinical data for Deramiocel and did not obtain FDA agreement before resubmitting a Biologics License Application for the drug. The release does not provide a court, docket number, judge or independent corroboration of the allegations.
Deramiocel is identified in the release as the drug at the center of the dispute. The text does not say what Capricor’s response is, and it does not describe any court ruling or regulatory action.
The law firm’s notice says shareholders who purchased CAPR during the class period are encouraged to contact the firm about possible lead plaintiff appointments. It also says lead plaintiff status is not required to participate in any recovery.
What happens next is not clear from the release. It says only that investors may contact the firm as the litigation moves forward.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()